The idea behind examining these conjugates on colon carcinoma cells was that (i) GnRH-R is expressed on different colon cancer cells [39,40], (ii) different GnRH analog-containing conjugates could inhibit colorectal tumor growth both in vitro and in vivo [3,12,24,39,40,41], and (iii) modification with butyrated Lys has been already proven to be a successful strategy to improve the effectivity of conjugates in different types of GnRH-R-positive tumor cells (e.g., melanoma cells [22], colon and breast cancer cells [21,42,43]). The gene discussed is GNRHR; the disease is breast cancer.